Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Accured Expenses: 2015-2024

Historic Change in Accured Expenses for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to $18.2 million.

  • Apellis Pharmaceuticals' Change in Accured Expenses fell 56.81% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 75.41%. This contributed to the annual value of $18.2 million for FY2024, which is 48.06% down from last year.
  • As of FY2024, Apellis Pharmaceuticals' Change in Accured Expenses stood at $18.2 million, which was down 48.06% from $35.0 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Change in Accured Expenses high stood at $55.0 million for FY2020, and its period low was -$10.4 million during FY2021.
  • Its 3-year average for Change in Accured Expenses is $15.6 million, with a median of $18.2 million in 2024.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Change in Accured Expenses crashed by 118.88% in 2021, and later spiked by 653.71% in 2023.
  • Apellis Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $55.0 million in 2020, then slumped by 118.88% to -$10.4 million in 2021, then surged by 39.26% to -$6.3 million in 2022, then spiked by 653.71% to $35.0 million in 2023, then crashed by 48.06% to $18.2 million in 2024.